Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 48.51M | -13.35M | 44.78M | 117.27M | 4.85M |
| Total Depreciation and Amortization | 8.22M | 8.22M | 8.21M | 8.27M | 8.52M |
| Total Amortization of Deferred Charges | 1.30M | 1.28M | 1.05M | 926.00K | 537.00K |
| Total Other Non-Cash Items | -27.01M | 46.65M | -17.42M | -102.76M | 8.06M |
| Change in Net Operating Assets | -7.00M | 5.89M | 9.29M | -10.62M | -6.17M |
| Cash from Operations | 24.02M | 48.69M | 45.92M | 13.09M | 15.80M |
| Capital Expenditure | -26.00K | -228.00K | -9.00K | -15.00K | -214.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -8.09M | -- | -- |
| Other Investing Activities | 321.14M | -94.12M | -10.01M | -353.43M | -10.45M |
| Cash from Investing | 321.12M | -94.35M | -18.10M | -353.45M | -10.67M |
| Total Debt Issued | 700.00M | -- | 0.00 | 460.00M | -- |
| Total Debt Repaid | -195.80M | -7.00K | -7.00K | -113.26M | -7.00K |
| Issuance of Common Stock | 8.60M | 7.65M | 9.30M | 25.74M | 8.24M |
| Repurchase of Common Stock | -60.35M | -21.73M | -344.00K | -15.22M | -145.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.98M | -50.00K | -617.00K | 52.38M | 6.91M |
| Cash from Financing | 546.43M | -14.13M | 8.33M | 409.65M | 15.00M |
| Foreign Exchange rate Adjustments | 39.00K | -44.00K | -590.00K | -400.00K | 2.29M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 2.82M | -2.74M |
| Net Change in Cash | 891.61M | -59.83M | 35.55M | 71.71M | 19.68M |